Anti-Mouse CD8a In Vivo Antibody - Low Endotoxin (2.43) 供应商 BioXCell 产品货号 ICH1045 产品报价 ￥询价/5mg ￥25mg ￥50mg ￥100mg 产品说明书 点击查看 购买方式 该货号产品已停产,请在bioxcell查找更优的替代产品。 产品新闻 背景资料 BioXCell公司成立于1997年美国,具有25年以上单克隆抗体和重组蛋白...
上海玉博生物科技有限公司 主要致力于“anti-human CD8a Purified HIT8a 25 ug eBioscience-14-0089-80”的生产销售。多年的“anti-human CD8a Purified HIT8a 25 ug eBioscience-14-0089-80”生产与销售的经验,与各行业新老用户建立了稳定的合作关系,我公司经营的产品名
上海玉博生物科技有限公司 主要致力于“anti-human CD8a PE RPA-T8 25 ug eBioscience-12-0088-80”的生产销售。多年的“anti-human CD8a PE RPA-T8 25 ug eBioscience-12-0088-80”生产与销售的经验,与各行业新老用户建立了稳定的合作关系,我公司经营的产品名称深受广大
荷瘤前一天腹腔注射,以后每3天注射一次。 剂量: anti-mouse CD4[GK1.5,100ug],anti-mouseCD8a[YTS169.4,100ug],anti-mouse Ly6G[1A8,200ug] 【BioXCell】 3.DCs的节律性抗肿瘤反应 免疫荧光immunofluorescence imaging+定量成像quantitative imaging EdU、BrdU(CTV、CSFV?)检测细胞增殖情况: 代替胸腺嘧啶T 4.Con...
CD8+ T cells were depleted in a subset of mice by intraperitoneal injection of CD8a depletion antibody (BioXcell, 2.43 clone), 3 times per week at 150 μg per animal. Drugs were given for the duration of the study, and comparable control treated with vehicle or rat IgG2a isotype ...
a,b, Early T cell expansion (day +4) or persistence (day +11) after infusion of transduced T cells against WT leukemia (a; exact P value of <0.0001) and CD19lo leukemia (b; exact P value of <0.0001). Transduced T cell populations were measured by coexpression of CD8a+TCRβ+EGFR...
CD8+ T cells were depleted in a subset of mice by intraperitoneal injection of CD8a depletion anti- body (BioXcell, 2.43 clone), 3 times per week at 150 μg per animal. Drugs were given for the duration of the study, and comparable control treated with vehicle or rat IgG2a isotype ...
CD8a (Clone 53-6.7) BioLegend Cat#100737; RRID: AB_10897101 CD45 (Clone 30-F11) BioLegend Cat#103138; RRID: AB_2563061 PerCP-anti-TER119 BioLegend Cat#116225; RRID: AB_893637 inVivoMAb anti-mouse PD-L1 (B7-H1) Bio X Cell Cat#BE0101; RRID: AB_10949073 inVivoMAb anti-mouse ...
Using single-cell RNA sequencing, we found that APG-2575 polarized M2-like immunosuppressive macrophages toward the M1-like immunostimulatory phenotype with increased CCL5 and CXCL10 secretion, restoring T-cell function and promoting a favorable immunotherapy response. Mechanistically, we demonstrated that...
Upon an average volume of 200 mm3, mice were randomized in different treatment groups: RT + PBS + IgG (LFT-2, BioXcell), RT + L19-IL2 + IgG, RT + PBS + aPD-L1 (10F.9G2, BioXcell), and RT + L19-IL2 + aPD-L1. Tumors were locally irradiated with 5 Gy (CT26) or 10 Gy ...